New Drugs for CNS, Endocrine, and Infectious Diseases

Total Page:16

File Type:pdf, Size:1020Kb

New Drugs for CNS, Endocrine, and Infectious Diseases continuing education for pharmacists Volume XXXV, No. 12 New Drugs for CNS, Endocrine, and Infectious Diseases Karen L. Kier, PhD, MSc, R.Ph., BCPS, BCACP, CTTS, Professor of Clinical Pharmacy, Director of Drug and Health Information, Raabe College of Pharmacy, Ohio Northern University Dr. Karen Kier has no relevant financial being channeled through restricted including life-threatening and relationships to disclose. distribution systems. Some of these fatal events, as well as a caution drugs are not FDA-approved for for immune-mediated disorders of Goal. The goal of this lesson is first-line therapy, but rather offer the skin and liver. Patients need to to provide information on central viable alternatives when first-line have routine liver testing and phar- nervous system drugs approved by drugs fail. In addition, many of the macists should counsel patients to the Food and Drug Administration new drugs are for rare conditions comply with their clinic visits. (FDA) in 2016; endocrinology and that often do not have many treat- Patients on daclizumab must infectious disease new drugs; and ment options. FDA approved sev- be enrolled in the REMS program the new herpes zoster vaccine. eral orphan drugs, as well as drugs prior to administration of the for rare genetic diseases in 2016. drug. Despite safety concerns, the Objectives. At the completion of FDA also approved new indications clinical trials showed that patients this activity, the participant will be or formulations for drugs already had fewer relapses with the ac- able to: on the market with many of these tive drug. One trial that combined 1. recognize the targeted pa- being oncology agents or monoclo- daclizumab with interferon beta-1a ® thologies for the new drugs dis- nal antibody therapy. This lesson (Avonex ) for 144 weeks showed cussed in this lesson; will include CNS drugs approved a statistically and clinically sig- 2. select the indication(s), phar- in 2016, new drugs for endocrine nificant reduction in relapses. A macologic action(s), clinical appli- and infectious disease, and the new second 52-week study which com- cations, dosing regimens, mode of herpes zoster vaccine. pared daclizumab with placebo also administration, and availability for showed a significant reduction in each drug; Central Nervous System MS relapses. 3. list the most relevant ad- Prior to initiating daclizumab, ® verse effects, warnings, precau- Daclizumab (Zinbryta [zin- patients need to be screened for tions, contraindications, and BRIGHT-ta], AbbVie, Inc. and hepatitis B and C, and treatment significant drug-drug or drug-food Biogen). In May of 2016, FDA should be avoided in patients with interactions reported with these approved daclizumab injection as a severe active infection including medications; and a joint submission from AbbVie, tuberculosis. Patients with hepatic 4. list important patient coun- Inc. and Biogen. Daclizumab is dysfunction should not be started seling information to convey to an interleukin-2 receptor blocking on daclizumab. ® patients and/or caregivers. antibody that received approval Zinbryta is supplied as a for the treatment of adult patients 150 mg/1mL prefilled syringe with Many new drugs were approved in with relapsing forms of multiple no preservatives. It is administered 2016 and early 2017 for treatment sclerosis (MS). Due to safety risks, monthly as a 150 mg subcutaneous of diseases in the central nervous it should be reserved for patients injection. If the patient misses a system (CNS), endocrine system who have failed or had an inad- dose, the pharmacist should coun- and for infectious diseases. The equate response to two or more MS sel him/her to administer the dose trend in drug approvals contin- drugs. This is a long-acting medica- as soon as possible, if it is within ues to include more drugs with tion that can be self-administered two weeks of the missed dose. If FDA-mandated Risk Evaluation by the patient once monthly. the missed dose is more than two and Mitigation Strategies (REMS) Daclizumab has a Boxed weeks late, the patient should skip programs with many of those drugs Warning for severe liver injury, that dose and administer the next Table 1 CNS drugs approved in 2016 Generic Indication Dose Dosage Form Side Effects (Trade Name) Daclizumab relapsing 150 mg subcutaneous Boxed Warning: liver injury; immune- (Zinbryta®) multiple MS monthly injection mediated disorders of skin and liver Phentermine weight 8 mg three 8 mg scored pulmonary and cardiovascular hydrochloride loss times a day tablets complications (Lomaira™) Pimavanserin Parkinson’s 34 mg 17 mg kidney dysfunction, peripheral edema, (Nuplazid®) disease daily tablets confusion; Boxed Warning: risk of death in elderly patients with dementia dose at the next monthly scheduled should be aware that patients on monitor the patient’s blood pres- time. Patients should be counseled daclizumab should not receive live sure while taking this medication to never double the dose. vaccines during treatment and up to make sure that patients main- Daclizumab syringes should to four months after discontinua- tain good blood pressure control. be stored in the refrigerator and tion of treatment. Consideration The usual dose of Lomaira™ is never frozen. Counsel patients should be given for any necessary 8 mg three times per day, 30 min- to remove the syringe from the immunizations a patient may re- utes before meals. It is important refrigerator and allow to warm to quire prior to starting therapy. to counsel patients that, to be ef- room temperature for 30 minutes fective, the medication needs to be prior to injection. It is important Phentermine hydrochloride taken 30 minutes prior to a meal. that patients are trained on proper (Lomaira™ [low-MAIR-a], KVK- The butterfly-shaped 8 mg tablet administration technique and that Tech, Inc.) received FDA approval is scored so patients can split the they understand how to properly on September 13, 2016. Phenter- tablet if a lower dose is needed. dispose of the used syringe. The mine is a sympathomimetic amine Pharmacists should be aware syringe needs to be protected from anorectic meant for short-term use that Lomaira™ is intended for light while being stored and phar- in managing weight. It is indicated short-term treatment. This prod- macists should encourage patients for patients with an initial body uct is a C-IV controlled substance to leave the syringe in its protected mass index (BMI) ≥30 kg/m2 or ≥27 and is subject to state and federal box during storage. Patients should kg/m2 in the presence of other risk regulations pertaining to controlled not attempt to heat or warm the factors such as diabetes, hyperlip- substances and medications used to syringe by any manner other than idemia, and/or controlled hyperten- facilitate weight loss. allowing the syringe to remain at sion. room temperature. If the injection Phentermine has been on the Pimavanserin (Nuplazid® [NEW- is not given once it reaches room market in various formulations plaz-id]) was approved by FDA as temperature, the syringe may be in the past for the same weight novel treatment of Parkinson’s dis- used within 30 days, but should loss and obesity indications as ease psychosis in 2016. Pimavan- never be returned to the refrig- Lomaira™. There were concerns serin was given FDA breakthrough erator once it has reached room with these phentermine products status. Clinical studies showed it temperature. relating to the adverse event profile was superior to placebo in decreas- Due to potential liver dysfunc- and the development of pulmonary ing the frequency and/or severity of tion, pharmacists should counsel arterial hypertension and other hallucinations and delusions with- patients on avoiding medications pulmonary and cardiovascular out worsening the primary motor that can cause liver damage, which complications. The difference with symptoms of Parkinson’s disease. can include herbal and over-the- Lomaira™ is with the dose and This is because pimavanserin is a counter medications such as acet- dosage form. Lomaira™ labeling non-dopaminergic, selective sero- aminophen and green tea extract. still contains caution for side ef- tonin inverse agonist (SSIA) and Daclizumab can suppress the im- fects similar to previous products. is considered a second-generation mune system and patients should Pharmacists should counsel pa- antipsychotic. be counseled to notify a health tients to be aware of this potential Pimavanserin is dosed orally professional if they have signs and and to contact a healthcare pro- at 34 mg daily. However, pima- symptoms of an infection. fessional if they experience any vanserin has significant drug-drug Immunizing pharmacists of these effects. Pharmacists can interactions with CYP3A4 drugs. In patients taking concomitant CYP3A4 inhibitors, such as keto- Table 2 conazole, the daily dose should be Newly-approved endocrine formulations/drugs decreased to 17 mg while patients taking CYP3A4 inducers should Generic Indication Dose Dosage Form (Trade Name) still receive 34 mg daily but be monitored for changes in efficacy of Insulin aspart Types 1 and 2 patient- pre-filled FlexTouch the drug. The American Psychiatric (Fiasp®) diabetes based pen and vials, Association recommends that any 100 Units/mL for patient taking an antipsychotic subcutaneous injection medication be gradually tapered off to avoid withdrawal symptoms. Lixisenatide Type 2 10 mcg/day pre-filled pen for Not to stop taking this medication (Adlyxin™) diabetes x 14 days, subcutaneous injection abruptly is a critical counseling then 20 mcg daily point for patients and caregivers. ® Nuplazid is available as a Abaloparatide osteoporosis 80 mcg pre-filled pen for 17 mg tablet. It can be taken with- (Tymlos™) daily subcutaneous out regard to meals or food intake. injection Pimavanserin has an elimina- tion half-life of 57 hours with an active metabolite that has an elimi- patients to become more confused; to manage their blood sugar. nation half-life of approximately patients and caregivers should be Patients should be instructed and 200 hours.
Recommended publications
  • Review of Current Real-World Experience with Teriparatide As Treatment of Osteoporosis in Different Patient Groups
    Journal of Clinical Medicine Review Review of Current Real-World Experience with Teriparatide as Treatment of Osteoporosis in Different Patient Groups Barbara Hauser 1,2,* , Nerea Alonso 2 and Philip L Riches 1,2 1 Rheumatic Disease Unit, Western General Hospital, NHS Lothian, Edinburgh EH4 2XU, UK; [email protected] 2 Rheumatology and Bone Disease Unit, Centre for Genomic and Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK; [email protected] * Correspondence: [email protected] Abstract: Teriparatide has proven effective in reducing both vertebral and non-vertebral fractures in clinical trials of post-menopausal and glucocorticoid-induced osteoporosis. Widespread adoption of Teriparatide over the last two decades means that there is now substantial experience of its use in routine clinical practice, which is summarized in this paper. Extensive real-world experience of Teriparatide in post-menopausal osteoporosis confirms the fracture and bone density benefits seen in clinical trials, with similar outcomes identified also in male and glucocorticoid-induced osteoporosis. Conversely, very limited experience has been reported in pre-menopausal osteoporosis or in the use of Teriparatide in combination with other therapies. Surveillance studies have identified no safety signals relating to the possible association of Teriparatide with osteosarcoma. We also review the evidence for predicting response to Teriparatide in order to inform the debate on where best to use Teriparatide in an increasingly crowded therapeutic landscape. Citation: Hauser, B.; Alonso, N.; Riches, P.L. Review of Current Keywords: Teriparatide; anabolic treatment; osteoporosis; fracture Real-World Experience with Teriparatide as Treatment of Osteoporosis in Different Patient Groups.
    [Show full text]
  • The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands
    The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands Clare Louise Wishart Submitted in accordance with the requirements for the degree of Doctor of Philosophy of Science University of Leeds School of Biomedical Sciences Faculty of Biological Sciences September 2013 I Intellectual Property and Publication Statements The candidate confirms that the work submitted is her own and that appropriate credit has been given where reference has been made to the work of others. This copy has been supplied on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement. The right of Clare Louise Wishart to be identified as Author of this work has been asserted by her in accordance with the Copyright, Designs and Patents Act 1988. © 2013 The University of Leeds and Clare Louise Wishart. II Acknowledgments Firstly I would like to offer my sincerest thanks and gratitude to my supervisor, Dr. Dan Donnelly, who has been nothing but encouraging and engaging from day one. I have thoroughly enjoyed every moment of working alongside him and learning from his guidance and wisdom. My thanks go to my academic assessor Professor Paul Milner whom I have known for several years, and during my time at the University of Leeds he has offered me invaluable advice and inspiration. Additionally I would like to thank my academic project advisor Dr. Michael Harrison for his friendship, help and advice. I would like to thank Dr. Rosalind Mann and Dr. Elsayed Nasr for welcoming me into the lab as a new PhD student and sharing their experimental techniques with me, these techniques have helped me no end in my time as a research student.
    [Show full text]
  • Novel Therapies in Osteoporosis: PTH-Related Peptide Analogs and Inhibitors of Sclerostin
    62 2 Journal of Molecular T D Rachner et al. Novel anabolic osteoporosis 62:2 R145–R154 Endocrinology treatments REVIEW Novel therapies in osteoporosis: PTH-related peptide analogs and inhibitors of sclerostin Tilman D Rachner1,2,3, Lorenz C Hofbauer1,2,3,4, Andy Göbel1,3 and Elena Tsourdi1,2,3 1Department of Medicine III, Technische Universität Dresden Medical Center, Dresden, Germany 2Center for Healthy Aging, Technische Universität Dresden Medical Center, Dresden, Germany 3German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ), Dresden, Germany 4Center for Regenerative Therapies Dresden, Technische Universität Dresden, Dresden, Germany Correspondence should be addressed to T D Rachner: [email protected] Abstract Bone-forming approaches to treat patients with severe osteoporosis are effective, but Key Words treatment options are limited, and there is an unmet clinical need for additional drugs. f PTH This review discusses two novel and advanced anabolic therapeutic concepts that f PTH-related protein have successfully completed phase 3 trials. Romosozumab is a monoclonal antibody f abaloparatide that targets the Wnt inhibitor sclerostin. Two phase 3 trials (FRAME and ARCH) of f sclerostin romosozumab for the treatment of postmenopausal osteoporosis have been completed. f sclerostin antibody Both trials successfully reached their primary endpoint by reducing vertebral fractures by f romosozumab 75% compared to placebo (FRAME trial) and 48% compared to alendronate (ARCH trial), respectively. Abaloparatide is a PTH-related protein (PTHrP) analog that has displayed bone anabolic activity. In the phase 3 ACTIVE trial, abaloparatide was compared to placebo and teriparatide for 18 months in postmenopausal women who had already experienced an osteoporotic fracture.
    [Show full text]
  • NMR Spectroscopy for Protein Higher Order Structure Similarity Assessment in Formulated Drug Products
    molecules Article NMR Spectroscopy for Protein Higher Order Structure Similarity Assessment in Formulated Drug Products Deyun Wang 1, You Zhuo 2, Mike Karfunkle 3, Sharadrao M. Patil 2, Cameron J. Smith 4, David A. Keire 5 and Kang Chen 2,* 1 Northeast Medical Products Laboratory, Office of Regulatory Science, Office of Regulatory Affairs, U.S. Food and Drug Administration, Jamaica, NY 11433, USA; [email protected] 2 Division of Complex Drug Analysis, Office of Testing and Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA; [email protected] (Y.Z.); [email protected] (S.M.P.) 3 Division of Pharmaceutical Analysis, Office of Testing and Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, St. Louis, MO 63110, USA; [email protected] 4 Division of Liquid Based Products I, Office of Lifecycle Drug Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA; [email protected] 5 Office of Testing and Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, St. Louis, MO 63110, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-240-402-5550 Abstract: Peptide and protein drug molecules fold into higher order structures (HOS) in formulation and these folded structures are often critical for drug efficacy and safety. Generic or biosimilar drug Citation: Wang, D.; Zhuo, Y.; products (DPs) need to show similar HOS to the reference product.
    [Show full text]
  • AACE Annual Meeting 2021 Abstracts Editorial Board
    June 2021 Volume 27, Number 6S AACE Annual Meeting 2021 Abstracts Editorial board Editor-in-Chief Pauline M. Camacho, MD, FACE Suleiman Mustafa-Kutana, BSC, MB, CHB, MSC Maywood, Illinois, United States Boston, Massachusetts, United States Vin Tangpricha, MD, PhD, FACE Atlanta, Georgia, United States Andrea Coviello, MD, MSE, MMCi Karel Pacak, MD, PhD, DSc Durham, North Carolina, United States Bethesda, Maryland, United States Associate Editors Natalie E. Cusano, MD, MS Amanda Powell, MD Maria Papaleontiou, MD New York, New York, United States Boston, Massachusetts, United States Ann Arbor, Michigan, United States Tobias Else, MD Gregory Randolph, MD Melissa Putman, MD Ann Arbor, Michigan, United States Boston, Massachusetts, United States Boston, Massachusetts, United States Vahab Fatourechi, MD Daniel J. Rubin, MD, MSc Harold Rosen, MD Rochester, Minnesota, United States Philadelphia, Pennsylvania, United States Boston, Massachusetts, United States Ruth Freeman, MD Joshua D. Safer, MD Nicholas Tritos, MD, DS, FACP, FACE New York, New York, United States New York, New York, United States Boston, Massachusetts, United States Rajesh K. Garg, MD Pankaj Shah, MD Boston, Massachusetts, United States Staff Rochester, Minnesota, United States Eliza B. Geer, MD Joseph L. Shaker, MD Paul A. Markowski New York, New York, United States Milwaukee, Wisconsin, United States CEO Roma Gianchandani, MD Lance Sloan, MD, MS Elizabeth Lepkowski Ann Arbor, Michigan, United States Lufkin, Texas, United States Chief Learning Officer Martin M. Grajower, MD, FACP, FACE Takara L. Stanley, MD Lori Clawges The Bronx, New York, United States Boston, Massachusetts, United States Senior Managing Editor Allen S. Ho, MD Devin Steenkamp, MD Corrie Williams Los Angeles, California, United States Boston, Massachusetts, United States Peer Review Manager Michael F.
    [Show full text]
  • 2017 Fda Peptide Harvest
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 April 2018 doi:10.20944/preprints201804.0126.v1 Peer-reviewed version available at Pharmaceuticals 2018, 11, 42; doi:10.3390/ph11020042 1 Review 2 2017 FDA PEPTIDE HARVEST 3 Othman Al Musaimi,1,2,# Danah Alshaer, 1,2,# Beatriz G. de la Torre,3,* Fernando Albericio,2,4,5.* 4 1 College of Health Sciences, University of KwaZulu-Natal, Durban 4000, South Africa 5 2 School of Chemistry, University of KwaZulu-Natal, Durban 4001, South Africa 6 3 KRISP, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa 7 4 CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine, University of 8 Barcelona, 08028 Barcelona, Spain 9 5 Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain 10 * Correspondence: [email protected]; [email protected]; Tel.: +27-614009144 11 12 13 Abstract: 2017 was an excellent year in terms of new drugs (chemical entities and biologics) 14 approved by the FDA, with a total of forty-six. In turn, one of the highlights was the number of 15 peptides (six) included in this list. Here, the six peptides are analysed in terms of chemical structure, 16 synthetic strategy used for their production, source, biological target, and mode of action. 17 Keywords: pharmaceutical market; drugs; drug discovery; solid-phase peptide synthesis 18 Introduction 19 The financial investment associated with the pharmaceutical industry is one of the largest in the 20 industrial sector—surpassed only by the telecommunications sector. However, the number of new 21 products (drugs) entering the market each year is relatively low.
    [Show full text]
  • The European Pharmacopoeia (Ph. Eur.)
    THE EUROPEAN DIRECTORATE FOR THE QUALITY OF MEDICINES & HEALTHCARE (EDQM) European Directorate for the Quality of Medicines & HealthCare • A Council of Europe Directorate, based on the Convention on the Elaboration of a European Pharmacopoeia (PA, 1964) • Mission: to contribute to a basic human right: access to good quality medicines and healthcare • See www.edqm.eu for further information 2 ©2020 EDQM, Council of Europe. All rights reserved. Key players for the quality of medicines in Europe National Authorities EU Coordination of scientific DG Health and resources from MS Food Safety Licensing Authorities Inspectorates Control Laboratories Pharmacopoeia Authorities Pharmaceutical legislation National Authorities EU & non-EU European Pharmacopoeia OMCL, Certification, Healthcare…. 3 ©2020 EDQM, Council of Europe. All rights reserved. •EDQM Laboratory •Established in 1967 •Located in Strasbourg, France • - Analytical Chemistry Division • - Biological Section 4 ©2020 EDQM, Council of Europe. All rights reserved. Role of the EDQM Laboratory European • establish/monitor Ph. Eur. reference substances (CRS) Pharmacopoeia • support elaboration of Ph. Eur. monographs / chapters (Ph. Eur.) • support the biological standardisation programme European • support the annual PTS programme OMCL network WHO • establish/monitor ICRS (Ref. Standards for the Ph. Int.) • establish/monitor ISA (Int’l Standards for Antibiotics) • participate in int’l studies on RS 5 ©2020 EDQM, Council of Europe. All rights reserved. European Pharmacopoeia Reference Standards for Biologicals Frank Jung, Ph.D. EDQM Laboratory Department Biological Section 6 ©2020 EDQM, Council of Europe. All rights reserved. The European Pharmacopoeia (Ph. Eur.) A compendium of quality standards for substances for pharmaceutical use and medicinal products Legally binding in 39 countries signatories of the Ph.
    [Show full text]
  • Nitroglycerin Ointment Strengthened Bone
    16 OSTEOPOROSIS MARCH 2011 • CLINICAL ENDOCRINOLOGY NEWS Nitroglycerin Ointment Strengthened Bone BY MARY ANN MOON cerin or a matching placebo ointment to included in the analysis: 126 in the ni- The primary end point was change in a piece of onion skin that was taped to the troglycerin group and 117 in the placebo lumbar spine areal BMD after 2 years. FROM JAMA upper outer arm overnight, every night. group. A total of 106 subjects dropped Those who received active nitroglycerin opical nitroglycerin ointment rais- The study subjects were women aged 50 out because of headache, nausea, or al- showed a significant increase of about es bone mineral density, cuts re- years or older (mean age, 62 years) who lergic reaction, and another 51 “lost in- 7%, compared with women in the place- Tsorption, and alters bone struc- were at least 1 year past menopause. terest” or became ineligible. bo group, in that measure. ture so that bone strength is increased, None had osteoporosis, but all had BMD After randomization, another 30 sub- They also showed comparable increas- according to results of a double-blind T scores of 0 to –2.0 at the lumbar spine jects in the treatment group and 15 in the es in areal BMD at the total hip (6%) and trial in 243 women. and higher than –2.0 at the total hip. placebo group discontinued or were lost femoral neck (7%). Compared with place- The magnitude of improvement equals Of 400 women enrolled, only 243 re- to follow-up, including 26 who cited ad- bo users, the nitroglycerin group also or exceeds that observed with other ther- mained in the study long enough to be verse reactions including headache.
    [Show full text]
  • Moon Jung, Waters
    A Systematic Approach for Improving the Recovery of Hydrophobic Peptides during LC-MS Analyses November 2019 Moon Chul (Moon) Jung, Ph.D. Waters Corporation, Chemistry Technology Center R&D ©2019 Waters Corporation COMPANY CONFIDENTIAL 1 Proteins and peptides can be quite sticky! Molecule or ¡ Non-Specific Binding (NSB) or Non-Specific Adsorption (NSA) Surface – Biomolecules tend to adhere to any exposed surfaces. – Any chemical interaction can be the source of NSB, Non-polar Polar but most dominantly… Uncharged Charged Polar Polar o Polarity-based interactions, e.g., hydrophobic attraction o Ionic interactions, e.g., coulombic attraction Basic Acidic (cationic) (anionic) ¡ NSB of biomolecules is more difficult to deal with compared to NSB of small molecules – Biomolecules are larger and more complex than small molecules. o There may be multiple binding interactions between biomolecules. – Proteins may be cooperatively deformed during the adsorption process. o And may be permanently lost. ©2019 Waters Corporation COMPANY CONFIDENTIAL Figure from F. Poncin et al., J. Func. Biomater. 3(3), 528, 2012 2 How does Non-Specific Binding (NSB) affect analyses? 5 ng/mL [10µL] - WithoutLeuprolide + RP Dilution - 95:5 (MW- Waters Untreated1209.4) - Rep 1 hormone antagonist peptide 100 50x scale Technical Replicate 1 Minimal NSB 5 ng/mL [10µL] - Without + RP Dilution - 95:5 - Waters Untreated - Rep 1 100 Technical Replicate 2 CV: 1.7% Technical Replicate 3 (n = 3) % CV: 41.8% % (n = 3) Non-specific binding can lead to: – Low sensitivity – High variability
    [Show full text]
  • Scibx Highlights
    ANALYSIS FROM THE MAKERS OF AND NOvember 17, 2011 • vOLUme 4 / NUmber 45 THIS WEEK ANALYSIS Dampening COVER STORY 1 Dampening neuroinflammation A California team has shown that inhibiting MAGL reduces neuroinflammation neuroinflammation in a mouse model of Parkinson’s disease. The researchers are now investigating the By Joanne Kotz, Senior Editor small molecule’s effects in other neurodegenerative and A California team has shown that monoacylglycerol lipase, which con- neurological diseases, and newco Abide Therapeutics is trols levels of a pain-reducing metabolite in the brain, also regulates exercising an option to license the MAGL inhibitors. neuroinflammation.1 The researchers have proof of concept that a small TARGETS & MECHANISMS molecule inhibitor of the target blocks inflammation and decreases 4 SEMA4D in osteoporosis neurodegeneration in a mouse model of Parkinson’s disease, and they Tokyo researchers have suggested that blocking the are now studying the compound in additional neurodegenerative and membrane protein SemA4D could directly promote bone formation in osteoporosis, and they plan to investigate the neurological diseases. target for arthritis and bone metastasis. Vaccinex already Newco Abide Therapeutics is exercising an option to license the has an inhibitor in Phase I trials for cancer. monoacylglycerol lipase (MAGL) inhibitors. MAGL is a serine hydrolase enzyme that degrades TRANSLATIONAL NOTES 2-arachidonoylglycerol (2-AG), a ligand of pain-relieving cannabinoid 6 Cancer matchmaker Cancer research UK is brokering partnerships between its receptors in the brain. In 2008, stable of academics and companies looking for a stake in a team led by Benjamin Cravatt “Targeting MAGL might early cancer discoveries. AstraZeneca is the charity’s anchor identified a brain-permeable provide a combined pain collaborator with three projects, including one involving small molecule inhibitor of and anti-inflammatory Senectus Therapeutics.
    [Show full text]
  • Final List of R-DNA Based Drugs Approved in the Country.Xlsx
    Date of Sr. No Name of the firm Name of the Drug Indication Permission No. Dosage Form & strength Permission each vial contains 2000 IU, 1 Ethnor Limited r-hu-EPO 24-8-1993 Anaemia due to chronic renal failure Nil 4000 IU, 10,000 IU filgrastim is indicated to Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) Granulocyte colony Roche Products (India) Reduce the duration of neutropenia 2 stimulating factor 30-Sep-93 Nil Pvt.Ltd and neutropenia-related clinical (Filgrastim ) (Neupogen) sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT) Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic for the treatment of female infertility in the following situations: - anovulation (including polycystic ovarian disease, PCOD) in women who have been unresponsive to treatment with clomiphene citrate - FOLLITROPIN BETA 3 Organon India 14-1-1996 controlled ovarian
    [Show full text]
  • Pharmacology's Review File (Endocrine)
    Y Summary of (Hyperthyroidism &Hypothyroidism) *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** Q1: Patient with which one of the following drugs is need to be assessed with the thyroid function test frequently ? A- Lithium. for Hypo B- Amiodarone. for both Hyper & Hypo. C-Both of them Q2: Which one of the following describe the main mechanism of action of propylthiouracil ? A- Block the Conversion T3 into T4 in the peripheral. B- Destroys the parenchymal cells of thyroid gland by beta rays. C- Inhibit the peroxidase enzyme centrally in thyroid gland. Q3: What is the drug of choice in treatment of hyperthyroidism in pregnant women ? A-Methimazole. B- Propylthiouracil. C- Propranolol. Q4: Why propylthiouracil is drug of choice in treatment of hyperthyroidism in pregnancy ? A- It does Crosses placenta because it hydrophobic. B- It is highly protein bound. C-It has low incidence of delayed hypothyroidism. Q5: Which one of the following is recommended to be used before thyroidectomy to decrease the possibility of bleeding from thyroid vessels ? A- Thioamides. B- Radioactive iodine. C-Lugol's solution or (KI). Q6: Which one of the following describe the mechanism of action of radioactive iodine ? A- Decrease both vascularity & size of thyroid gland by inhibiting the mitosis. B- Destroys the parenchymal cells of thyroid gland by beta rays. C- Inhibit the peroxidase enzyme centrally in thyroid gland. Q7:Which one of the following line of treatment of hyperthyroidism acting by destruction of thyroid’s parenchyma due to emission of β rays ? A- Thioamides. B- Radioactive iodine. C- Lugol's solution Q8:Which one of the following line of treatment of hyperthyroidism may safe the life of patient especially if he has tachycardia and sever palpitation a long with her hyperthyroidism ? A- Thioamides.
    [Show full text]